Cecilia N.
- Country
- Sweden
- Department
- Onkologikliniken
Research Overview
- Evaluation of Extended Adjuvant Endocrine Therapy with Tamoxifen, Exemestane, Anastrozole, and Letrozole in High-Risk Luminal Breast Cancer Patients
- A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer
- Phase 3 Study of PF-07220060 and Fulvestrant Versus Investigator's Choice in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Post-CDK 4/6 Inhibitor Therapy
Data & Insights
Has run more than one trial at 52 of 194 partner sites.
Specializations
Breast Cancer Specialization
This investigator demonstrates extensive expertise in breast cancer treatment, with particular focus on various molecular subtypes including triple negative breast cancer and hormone receptor-positive disease.
- Triple-negative breast cancer management
- Early-stage breast cancer treatment
- HER2-negative breast cancer
The investigator's research encompasses innovative therapeutic approaches in early-stage disease settings.
Endocrine Therapy Research
Specialized focus on endocrine treatment optimization for breast cancer patients, including extended therapy approaches and treatment strategies for both pre- and postmenopausal women.
- Long-term endocrine therapy
- Aromatase inhibitor treatments
- Tamoxifen therapy protocols
The investigator explores extended treatment durations and switching strategies in hormonal therapy.
Therapeutic Innovation
Active involvement in evaluating novel therapeutic agents and treatment combinations, particularly in estrogen receptor-positive breast cancer.
- Combination chemotherapy approaches
- Novel endocrine agents
- Targeted therapeutic strategies
Research focuses on comparing emerging treatments with established therapeutic standards.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.